Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib

Background: Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in the management of hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), the optimal sequence of therapy is unclear. There are no clinical data on efficacy of everolimus in HR+ HER2-...

Full description

Bibliographic Details
Main Authors: Ajay Dhakal, Roby Antony Thomas, Ellis G Levine, Adam Brufsky, Kazuaki Takabe, Matthew G Hanna, Kristopher Attwood, Austin Miller, Thaer Khoury, Amy P Early, Saif Soniwala, Tracy O’Connor, Mateusz Opyrchal
Format: Article
Language:English
Published: SAGE Publishing 2020-07-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:https://doi.org/10.1177/1178223420944864

Internet

https://doi.org/10.1177/1178223420944864

Similar Items